82 filings
Page 3 of 5
8-K
1wkv7 palwxp8qei
14 May 21
Iterum Therapeutics Reports First Quarter 2021 Financial Results
7:15am
8-K
ye54oc
9 Apr 21
Other Events
7:30am
8-K
5ojg245gufvyq
16 Mar 21
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
4:30pm
8-K
f45p9bn
12 Mar 21
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
7:15am
8-K
3cuja5uw5bv7b465qo
22 Feb 21
Departure of Directors or Certain Officers
4:30pm
8-K
ebhl48ha0ke7yzw742t
11 Feb 21
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
12:00am
8-K
nbta2wvpkpa8xp
10 Feb 21
Iterum Therapeutics plc Announces $35.0 Million Registered
8:54am
8-K
rv0amr
5 Feb 21
Iterum Therapeutics plc Announces $10 Million Bought Deal
5:09pm
8-K
p0yxlv zhq4pilnj7
1 Feb 21
Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
5:00pm
8-K
aqjjs8z16tuf5x sztb
28 Jan 21
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem
4:16pm
8-K
sgc4kh7rqo10zi
23 Dec 20
Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors
7:20am
8-K
vrnmfou6
21 Dec 20
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
5:15pm
8-K
hkfmk20v22r3eljh0f2
16 Nov 20
Iterum Therapeutics Reports Third Quarter 2020 Financial Results
7:00am
8-K
esoqklp68 3omm
27 Oct 20
Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering
5:29pm
8-K
u5undb026lr6f ddf
30 Sep 20
Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections
4:15pm
8-K
hmbp3ma xzl
25 Sep 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K/A
gmp200ps
2 Sep 20
Iterum Therapeutics Announces Revised Results of Rights Offering
7:15am
8-K
glhve5
1 Sep 20
Iterum Therapeutics Announces Expiration and Preliminary Results of Rights Offering
4:05pm
8-K
koeonov2qeunmd4
11 Aug 20
Iterum Therapeutics Commences Rights Offering
8:38am
8-K
hryjv q7ad72
6 Aug 20
Iterum Therapeutics Reports Second Quarter 2020 Financial Results
7:00am